Companies /Healthcare
Novartis AG ADR
NYSE: NVS Drug Manufacturers - General
$140.79
▼ $0.14 (−0.10%) today
Markets closed · 10:07pm ET

Novartis (NVS) Q4 2024 Earnings

Reported Jan 31, 2025, 7:14am ET · SEC source
$1.98
Beat +11.44%
EPS · est. $1.78
$13.2B
Beat +2.57%
Revenue · est. $12.8B
+10.0%
Beating market
NVS vs S&P since report
1 quarter
Consecutive EPS misses

How Did NVS Stock React to Q4 2024 Earnings?

% change · around the report
−2.4%−1.6%−0.8%0Jan 31Jan 31report 7:14am ETearnings−1.0%−2.1%
−2.4%−1.6%−0.8%0Jan 31Jan 31earnings−1.0%−2.1%
NVS −2.1%S&P 500 −1.0%
−1.8%−0.9%0+0.9%Jan 31Jan 31report 7:14am ETearnings−1.0%−2.1%
−1.8%−0.9%0+0.9%Jan 31Jan 31earnings−1.0%−2.1%
NVS −2.1%NASDAQ −1.0%
−4%−2%0+2%Jan 30Feb 7report 7:14am ETearnings−1.1%−0.7%
−4%−2%0+2%Jan 30Feb 7earnings−1.1%−0.7%
NVS −0.7%S&P 500 −1.1%
−4%−2%0+2%Jan 30Feb 7report 7:14am ETearnings−0.9%−0.7%
−4%−2%0+2%Jan 30Feb 7earnings−0.9%−0.7%
NVS −0.7%NASDAQ −0.9%
−0.03%
Day of report
+0.73%
Next session
+1.47%
One week
+6.84%
30 days

S&P 500 over the same 30 days: −3.12%.

Did NVS Beat Earnings? Q4 2024 Results

Yes. Novartis reported Q4 2024 earnings of $1.98 a share on Jan 31, 2025, beating the $1.78 consensus estimate by 11.4%. Revenue was $13.2B against a $12.8B estimate.

Novartis closed out 2024 with a notably strong fourth quarter, posting core earnings per share of $1.98 against a consensus estimate of $1.78, a beat of 11.44%, while revenue of $13.15 billion topped expectations by 2.57% and grew 11.7% year over year. The Swiss drugmaker's outperformance was anchored by broad-based volume gains across its innovative medicines portfolio, with Entresto leading the charge at $2.18 billion in Q4 sales, up 33%, and Kesimpta and Kisqali each surging 48% to $950 million and $902 million, respectively. The US market proved especially powerful, generating $6.00 billion in quarterly sales, up 26%, as Kisqali's recently launched early breast cancer indication accelerated domestic demand. Q4 operating income climbed 37% to $3.53 billion, with core operating income margin reaching 36.9% for the quarter. Shares rose on the results, and the company issued an upbeat 2025 outlook calling for high single to low double-digit core operating income growth, excluding currency effects.

Key Takeaways
  • Entresto sustained robust demand-led growth from continued GDMT adoption in heart failure
  • Kisqali strong momentum from recently launched early breast cancer indication with 66% cc US growth
  • Kesimpta demand-driven growth across all regions with strong access in relapsing MS
  • Cosentyx growth driven by recent HS indication and IV formulation launches in the US
  • Volume contributed 15 percentage points to Q4 growth
  • Pricing had a positive 2 percentage point impact, benefiting from revenue deduction adjustments mainly in the US
  • Lower weighted average number of shares outstanding boosted EPS
  • SG&A expenses as a percentage of net sales decreased by 3.6 percentage points (cc)

NVS YoY Financials

Q4 2024 vs Q4 2023 · SEC filings Q4 2023 Q4 2024
$0$4.0B$8.0B$12.0B$11.8B$13.2BRevenue$8.8B$10.2BGross Profit$2.6B$3.5BOperating Income$8.5B$2.8BNet Income
$0$4.0B$8.0B$12.0BRevenueGross ProfitOperating IncomeNet Income
NVS income statement, Q4 2024 versus Q4 2023
Metric Q4 2024 Q4 2023 Year over year
Revenue $13.2B $11.8B +11.7%
Gross Profit $10.2B $8.8B +16.9%
Operating Income $3.5B $2.6B +36.7%
Net Income $2.8B $8.5B −66.8%

NVS Revenue by Segment

Entresto$2.2B+33.0%
Cosentyx$1.6B+22.0%
Kisqali$902.0M+48.0%
Kesimpta$950.0M+48.0%
Pluvicto$351.0M+29.0%
Promacta/Revolade$583.0M+4.0%
Tafinlar + Mekinist$527.0M+8.0%
Jakavi$487.0M+10.0%

NVS Revenue by Geography

Rest of World
United States$6.0B+26.0%
Europe$4.0B+7.0%
Asia Pacific$2.3B+4.0%
China
Americas$876.0M+23.0%

Figures from SEC filings and company reports. Not investment advice.